A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more efficient ways to detect and ...

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCCmaMICVO ...

Concurrent with Dr. Gormley’s appointment to Aktis’ Board of Directors, current Board members Helen Kim and Oleg Nodelman plan to step down from Aktis’ Board of Directors, effective May 20, 2026.

A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest ...

At AACR 2026, scientists showcased advances in radiotherapeutics, antibody-drug conjugates, T cell engagers, and ...

Early data show the cancer drug mocertatug rezetecan (Mo‑Rez) delivering response rates above 60% in patients with ovarian and endometrial cancers that have returned after earlier treatment ...

Faculty of Medicine in Canada have developed a new targeted cancer therapy that can precisely seek out and destroy tumor ...

'Nobody's creators are back with another kick-ass Odenkirk movie.

Homozygous but not heterozygous loss of Pten in sporadic mouse models of SHH-medulloblastoma greatly accelerates tumor formation, not metastasis, through increased survival of differentiated cells and ...

Methodology that is not complete, as well as discrepancies regarding the proposed mode of action of lipoxin A4, are significant weaknesses.